Significant progresss has been made in understanding the mechanisms by which intravenous immunoglobulins (IVIg) exert immunomodulatory effects in the treatment of autoimmune diseases. A unique property of immunoglobulins is the diversity of variable (V) regions. The evidence discussed in this communication supports our notion that the diversity of V regions in IVIg preparations is a determining factor for the antiinflammatory substitutive and immunomodulatory functions of IVIg therapy. We have demonstrated the presence in IVIg, of anti-idiotypic antibodies directed against various autoantibodies. The ability of IVIg to interact through V regions with complementary V regions of antibodies and antigen receptors as well as with relevant soluble and surface molecules provides the basis for inducing the selection of immune repertoires. The study of the mechanisms by which IVIg mediates selection of autoreactive repertoires is essential for our understanding of the mechanisms underlying the emergence of pathological autoimmunity and of the physiological role of natural antibodies in the establishment and maintenance of tolerance to self and homeostasis of autoreactivity in healthy individuals.
Avrameas S. (1991) Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton'. Immunol Today12: 154-159.
2.
Varela F., Coutinho A. (1991) Second generation immune networks. Immunol Today12: 159-166.
3.
Blasczyk R., Westhoff U., Grossewilde H. (1993) Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet341: 789-790.
4.
Eibl MM, Wedgwood RJ (1993) Intravenous immunoglobulin: a review. In: Rosen FS and Seligmann M. (eds), Immunodeficiencies. Vol. pp. 659-688. Harwood Academic Publishers, Chur.
5.
Imbach P., Barandun S., D'Apuzzo V. et al. (1981) High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lanceti: 1228-1230.
6.
Blanchette VS , Imbach P., Andrew M. (1994) A prospective randomized trial of intravenous immunoglobulin G, oral prednisolone and intravenous anti-D in childhood acute idiopathic thrombocytopenic purpura . Lancet344: 703-707.
7.
Lalezari P., Korshidi M., Petrosova M. (1986) Autoimmune neutropenia of infancy. J Pediatr109: 764-769.
8.
McGuire WA, Yang HH, Bruno E. et al. (1987) Treatment of antibody-mediated pure red-cell aplasia with high-dose intravenous gammaglobulin. N Engl J Med317: 1004-1008.
9.
McIntyre EA, Linch DC, Macey MG, Newland AC (1985) Successful response to intravenous immunoglobulin in autoimmune hemolytic anemia. Br J Haematol60: 387-388.
10.
Oda H., Honda A., Sugita K. (1985) High dose intact IgG infusion in refractory autoimmune hemolytic anemia (Evans syndrome). J Pediatr107: 744-746.
11.
Hughes R. (1996) Plasma exchange versus intravenous immunoglobulin for Guillain-Barré syndrome. Japan J Apheresis15: S12.
12.
Van der Meché Fga , Smith Pim , Dutch Guillain-Barré Study Group. (1992) A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome . N Engl J Med326: 1123-1129.
13.
Gajdos P., Outin H., Elkharrat D. et al. (1984) High-dose intravenous gammaglobulin for myasthenia gravis. Lanceti: 406-407.
14.
Sultan Y., Kazatchkine MD, Maisonneuve P., Nydegger UE (1984). Anti-idiotypic suppression of autoantibodies to Factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin . Lancetii: 765-768.
15.
Dalakas M., Illa I., Dambrosia J. et al. (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med329: 1993-2000.
16.
Jayne Drw , Davies M., Fox C., Lockwood CM (1991) Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancetii: 1137-1139.
17.
Lehoang P., Jobin D., Kazatchkine MD (1996). Treatment of birdshot retinochoroidopathy with intravenous immunoglobulins. Am J Ophthalmol submitted.
18.
Gelfand EW, Esterl B., Mazer BD (1994) Benefit of 12% solution of intravenous immunoglobulin in the treatment of steroid-dependent asthma. In: Kazatchkine MD and Louwagie A. (eds), Immunoglobulins: extending the horizon. Vol. pp. 49-62. Parthenon Publishing, London.
19.
Debre M., Bonnet MC, Fridman WH et al. (1993) Infusion of Fcγ fragments for the treatment of children with acute immune thrombocytopenic purpura. Lancet342: 945-949.
20.
Clarkson SB , Bussel JB, Kimberly RP et al. (1986) Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody. N Engl J Med314: 1236-1239.
21.
Fehr J., Hofmann V., Kappeler U. (1982) Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gammaglobulin. N Engl J Med306: 1254-1258.
22.
Salama A., Mueller-Eckhardt C., Kiefel V. (1983) Effect of intravenous immunoglobulin in immune thrombocytopenia. Competitive inhibition of reticuloendothelial system function by sequestration of autologous red blood cells?Lancetii: 193-195.
23.
Kimberly RP et al. (1984) Modulation of mononuclear phagocyte function by intravenous gamma globulin. J Immunol132: 745-750.
24.
Fridman W. (1993) Regulation of B-cell activation and antigen presentation by Fc receptors. Curr Opin Immunol5: 355-360.
25.
Unkeless JC , Scigliano E., Freedman VH (1988) Structure and function of human receptors for IgG. Ann Rev Immunol6: 251- 281.
26.
Basta M. et al. (1989) High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearance. Blood74: 326-333.
27.
Basta M., Kirshbom P., Frank MM, Fries LF (1989). Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model. J Clin Invest84: 1974-1981.
28.
Basta M., Dalakas MC (1994) High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complements fragments. J Clin Inv94: 1729-1735.
29.
Abe Y., Horiuchi A., Miyake M., Kimura S. (1994) Anti-cytokine nature of human immunoglobulin: one possible mechanism of the clinical effect of intravenous therapy. Imm unol Rev139: 5-19.
30.
Bendtzen K. , Svenson M., Jonsson V., Hippe E. (1990) Autoantibodies to cytokines - friends or foes? Immunol Today11: 167-169.
31.
Svenson M., Hansen MB, Bendtzen K. (1990) Distribution and characterization of autoantibodies to interleukin 1 α in normal human sera. Scand J Immunol32: 695-701.
32.
Rossi F., Kazatchkine MD (1989) Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. J Immunol143:? 4104-4109.
33.
Van Doorn PA , Rossi F., Brand A. et al. (1990) On the mechanism of high dose intravenous immunoglobulin treatment of patients with chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol29: 57-64.
34.
Rossi F., Jayne Drw, Lockwood CM, Kazatchkine MD (1991) Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis. Clin Exp Immunol83: 298-303.
35.
Berchtold P. , Dale GL, Tani P., McMillan R. (1989) Inhibition of autoantibody binding to platelet glycoprotein IIb/IIIa by anti-idiotypic antibodies in intravenous immunoglobulins. Bl ood74: 2414-2417.
36.
Liblau R., Gajdos P., Bustarret FA et al. (1991) Intravenous gammaglobulin in myasthenia gravis: Interaction with anti-acetylcholine receptor autoantibodies. J Clin Immunol11: 128-131.
37.
Ronda N., Haury M., Nobrega A. et al. (1994) Analysis of natural and disease-associated autoantibody repertoires: anti-endothelial cells IgG autoantibody activity in the serum of healthy individuals and patients with systemic lupus erythematosus . Int Immunol6: 1651-1660.
38.
Caccavo D. et al. (1994) Antiidiotypes against antiphospholipid antibodies are present in normal polyspecific immunoglobulins for therapeutic use. JAutoimmunity7, 537-548.
39.
Fremeaux-Bacchi V., Maillet F., Berlan L., Kazatchkine MD (1992) Neutralizing antibodies against C3Nef in intravenous immunoglobulin . Lancet340: 63-64.
40.
Kazatchkine MD, Dietrich G., Hurez V. et al. (1994) V Region-mediated selection of autoreactive repertoires by intravenous immunoglobulin (IVIg) . Immunol Rev139: 79-107.
41.
Dekeyser F. et al. (1996) Pooled human immunoglobulins contain anti-idiotypes with reactivity against the 4B4/ P36 cross-reactive idiotype. Clin Exp Rheumatol14: 587-591.
42.
Rossi F., Dietrich G., Kazatchkine MD (1989) Antiidiotypes against autoantibodies in normal immunoglobulins: Evidence for network regulation of human autoimmune responses . Immunol Rev110: 135-149.
43.
Dietrich G. , Kazatchkine MD (1990) Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contain antiidiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotpye of human anti-thyroglobulin autoantibodies. J Clin Invest85: 620-625.
44.
Kaveri SV et al. (1993) Monoclonal anti-idiotypic antibodies against human anti-thyroglobulin autoantibodies recognize idiotypes shared by disease-associated and natural anti-thyroglobulin autoantibodies. Clin Immunol Immunopathol69: 333 - 340.
45.
Kaveri SV, Kang CY, Kohler H. (1990) Natural mouse and human antibodies bind to a peptide derived from a germline variable heavy chain: Evidence for evolutionary conserved self-binding locus. J Immunol145: 4207-4213.
46.
Tankersley DL (1994) Dimer formation in immunoglobulin preparations and speculations on the mechanisms of action of intravenous immunoglobulin in autoimmune diseases. Immunol Rev139: 159-172.
47.
Roux KH, Tankersley DL (1990) A view of the human idiotypic repertoire: Electron microscopic and immunologic analyses of spontaneous idiotype-anti-idiotype dimers in pooled human IgG. J Immunol144: 1387-1395.
48.
Tankersley DL , Preston MS, Finlayson JS (1988). Immunoglobulin G dimer: an idiotype-anti-idiotype complex. Mol Immunol25: 41-48.
49.
Rossi F., Guilbert B., Tonnelle C. et al. (1990) Idiotypic interactions between normal human polyspecific IgG and natural IgM antibodies. Eur J Immunol20: 2089-2094.
50.
Adib M., Ragimbeau J., Avrameas S., Ternynck T. (1990) IgG autoantibody activity in normal mouse serum is controlled by IgM. J Immunol145: 3807-3813.
51.
Hurez V., Kaveri SV, Kazatchkine MD (1993) Expression and control of the natural autoreactive IgG repertoire in normal human serum. Eur J Immunol23: 783-789.
52.
Marchalonis JJ, Kaymaz H., Dedeoglu F. et al. (1992) Human autoantibodies reactive with synthetic autoantigens from T-cell receptor β chain. Proc Natl Acad Sci USA89: 3325-3329.
53.
Vassilev T. , Gelin C., Kaveri SV et al. (1993) Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg). Clin Exp Immunol92: 369-372.
54.
Hurez V., Kaveri SV, Mouhoub A. et al. (1994) Anti-CD4 activity of normal human immunoglobulins G for therapeutic use (Intravenous immunoglobulin, IVIg). Therap Immunol1: 269-278.
55.
Kaveri S., Vassilev T., Hurez V. et al. (1996) Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use (IVIg). J Clin Invest97: 865 - 869.
56.
Kawada K., Terasaki PI (1987) Evidence for immunosuppression by high-dose gammaglobulin . Exp Hematol15: 133-136.
57.
Leung Dym , Gately M., Trumble A. et al. (1995) Bacterial superantigens induce T cell expression of the skin-selective homing receptor, the cutaneous lymphocyte-associated antigen, via stimulation of interleukin 12 production . J Exp Med181: 747-753.
58.
Van Schaik IN, Lundkvist I., Vermeulen M., Brand A. (1992) Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro. J Clin Immunol12: 325-334.
59.
Dietrich G. et al. (1993) Selection of the expressed B cell repertoire by infusion of normal immunoglobulin G in a patient with autoimmune thyroiditis. Eur J Immunol23: 2945-2950.
60.
Varela F., Andersson A., Dietrich G. et al. (1991) The population dynamics of antibodies in normal and autoimmune individuals. Proc Natl Acad Sci USA88: 5917-5921.
